Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 3
2000 7
2001 9
2002 12
2003 15
2004 23
2005 29
2006 29
2007 27
2008 33
2009 26
2010 12
2011 16
2012 16
2013 4
2014 7
2015 11
2016 11
2017 7
2018 7
2019 6
2020 5
2021 9
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

298 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data.
Efthimiou O, Taipale H, Radua J, Schneider-Thoma J, Pinzón-Espinosa J, Ortuño M, Vinkers CH, Mittendorfer-Rutz E, Cardoner N, Tanskanen A, Fusar-Poli P, Cipriani A, Vieta E, Leucht S, Tiihonen J, Luykx JJ. Efthimiou O, et al. Lancet Psychiatry. 2024 Feb;11(2):102-111. doi: 10.1016/S2215-0366(23)00366-8. Epub 2024 Jan 9. Lancet Psychiatry. 2024. PMID: 38215784
We analysed each registry separately to obtain hazard ratios (HRs) and 95% CIs for relapse within 6 months post-antipsychotic initiation as our main outcome. Interventions studied were antipsychotics, no antipsychotic use, and placebo. ...The joint real-world and RC …
We analysed each registry separately to obtain hazard ratios (HRs) and 95% CIs for relapse within 6 months post-antipsychotic initiat …
Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences.
Taipale H, Puranen A, Mittendorfer-Rutz E, Tiihonen J, Tanskanen A, Cervenka S, Lähteenvuo M. Taipale H, et al. Nord J Psychiatry. 2021 Jul;75(5):315-322. doi: 10.1080/08039488.2020.1854853. Epub 2020 Dec 17. Nord J Psychiatry. 2021. PMID: 33331804
OBJECTIVES: To compare the differences in prevalence of antipsychotic and adjunctive pharmacotherapy use among individuals with schizophrenia between Sweden and Finland during 2006-2016. METHODS: Nationwide register-based data were utilized for constructing two sepa …
OBJECTIVES: To compare the differences in prevalence of antipsychotic and adjunctive pharmacotherapy use among individuals with sc …
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Cuesta MJ, Peralta V, Zarzuela A. Cuesta MJ, et al. Schizophr Res. 2001 Mar 1;48(1):17-28. doi: 10.1016/s0920-9964(00)00112-2. Schizophr Res. 2001. PMID: 11278151 Review.
This study aimed to determine the effect of olanzapine and other antipsychotic drugs on cognitive functions after 6months of treatment. ...In summary, in patients suffering from chronic schizophrenia, atypical antipsychotic agents were associate …
This study aimed to determine the effect of olanzapine and other antipsychotic drugs on cognitive functions after 6months of t …
Cost comparisons of olanzapine and risperidone in treating schizophrenia.
Liu GG, Sun SX, Christensen DB, Luo X. Liu GG, et al. Ann Pharmacother. 2004 Jan;38(1):134-41. doi: 10.1345/aph.1C485. Ann Pharmacother. 2004. PMID: 14742807 Review.
OBJECTIVE: To review the literature on the healthcare costs associated with olanzapine and risperidone in treating schizophrenia. DATA SOURCES: Published English-language pharmacoeconomic studies on olanzapine and risperidone obtained through a MEDLINE search …
OBJECTIVE: To review the literature on the healthcare costs associated with olanzapine and risperidone in treating schizophrenia …
Association of smoking cigarettes, age, and sex with serum concentrations of olanzapine in patients with schizophrenia.
Horvat M, Kadija M, Ščavničar A, Živković M, Šagud M, Lovrić M. Horvat M, et al. Biochem Med (Zagreb). 2023 Oct 15;33(3):030702. doi: 10.11613/BM.2023.030702. Biochem Med (Zagreb). 2023. PMID: 37841771 Free PMC article.
INTRODUCTION: Olanzapine is an atypical antipsychotic drug which is effective in the treatment of schizophrenia. ...CONCLUSIONS: The serum olanzapine concentration was significantly lower in smoking than in non-smoking patients with schizophrenia …
INTRODUCTION: Olanzapine is an atypical antipsychotic drug which is effective in the treatment of schizophrenia. ...CON …
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
Kahn RS, Silverman BL, DiPetrillo L, Graham C, Jiang Y, Yin J, Simmons A, Bhupathi V, Yu B, Yagoda S, Hopkinson C, McDonnell D. Kahn RS, et al. Schizophr Res. 2021 Jun;232:45-53. doi: 10.1016/j.schres.2021.04.009. Epub 2021 May 17. Schizophr Res. 2021. PMID: 34015555 Free article. Clinical Trial.
AIM: A combination of olanzapine and samidorphan (OLZ/SAM) is in development for the treatment of patients with schizophrenia or bipolar I disorder and is intended to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain …
AIM: A combination of olanzapine and samidorphan (OLZ/SAM) is in development for the treatment of patients with schizophrenia …
Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia.
Haro JM, Novick D, Belger M, Jones PB. Haro JM, et al. Eur Psychiatry. 2006 Jan;21(1):41-7. doi: 10.1016/j.eurpsy.2005.12.001. Epub 2006 Jan 18. Eur Psychiatry. 2006. PMID: 16414249
Antipsychotic medication maintenance and the factors influencing it were analyzed using data from the SOHO study, a large observational study of the outcomes of antipsychotic treatment for schizophrenia in Europe. A total of 7186 adult patients in the outp …
Antipsychotic medication maintenance and the factors influencing it were analyzed using data from the SOHO study, a large observation …
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
Ono S, Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, Matsuda H, Sugawara N, Yasui-Furukori N, Okamoto K, Sagae T, Someya T. Ono S, et al. BMC Psychiatry. 2018 Jun 8;18(1):180. doi: 10.1186/s12888-018-1764-1. BMC Psychiatry. 2018. PMID: 29879941 Free PMC article.
The aim of the present study was to compare the levels of high-density lipoprotein (HDL)-cholesterol in Japanese schizophrenia patients medicated with olanzapine, risperidone, or aripiprazole monotherapy. ...For comparisons of HDL-cholesterol levels among the three …
The aim of the present study was to compare the levels of high-density lipoprotein (HDL)-cholesterol in Japanese schizophrenia patien …
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.
Cernea S, Dima L, Correll CU, Manu P. Cernea S, et al. Drugs. 2020 Nov;80(17):1763-1781. doi: 10.1007/s40265-020-01393-x. Drugs. 2020. PMID: 32930957 Review.
Fasting hyperglycemia, impaired glucose tolerance, prediabetes, and diabetes are frequently present in patients treated with second-generation antipsychotics (SGAPs) for schizophrenia, bipolar disorder, and other severe mental illnesses. These drugs are known to produce we …
Fasting hyperglycemia, impaired glucose tolerance, prediabetes, and diabetes are frequently present in patients treated with second-generati …
Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
Novick D, Ascher-Svanum H, Brugnoli R, Bertsch J, Hong J, Haro JM. Novick D, et al. J Nerv Ment Dis. 2012 Jul;200(7):637-43. doi: 10.1097/NMD.0b013e31825bfd95. J Nerv Ment Dis. 2012. PMID: 22759944
This post hoc study used data from the naturalistic Schizophrenia Outpatient Health Outcomes study, assessing the factors associated with starting antipsychotic monotherapy and the annual rate and duration of antipsychotic monotherapy among patients in …
This post hoc study used data from the naturalistic Schizophrenia Outpatient Health Outcomes study, assessing the factors asso …
298 results